Pilulka Lekarny AS (XPRA:PINK) Research & Development: Kč0 Mil (TTM As of Dec. 2025)


XPRA:PINK Pilulka Lekarny AS XPRA:PINK
49 GF Score
Price Kč114.50
GF Value Kč114.69
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Pilulka Lekarny AS Research & Development?

Pilulka Lekarny AS XPRA:PINK -0.43% 49 Research & Development is Kč0 Mil as of Dec. 2025. GuruFocus rates XPRA:PINK with a GF Score™ of 49/100 and a GF Value™ of Kč114.69 (Fairly Valued). The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Pilulka Lekarny AS's Research & Development for the six months ended in Dec. 2025 was Kč0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was Kč0 Mil.

Pilulka Lekarny AS  (XPRA:PINK) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Pilulka Lekarny AS Research & Development Related Terms

Pilulka Lekarny AS Research & Development Historical Data

* Premium members only.

The historical data trend for Pilulka Lekarny AS's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pilulka Lekarny AS Research & Development Chart

Pilulka Lekarny AS Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Pilulka Lekarny AS Semi-Annual Data
Dec20 Dec21 Dec22 Dec23 Jun24 Dec24 Dec25
Research & Development Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
XPRA:PINK
49GF Score
Pilulka Lekarny AS XPRA:PINK
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pilulka Lekarny AS Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was Kč0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of Kč0 Mil mean?
Pilulka Lekarny AS (XPRA:PINK) has a Research & Development of Kč0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Pilulka Lekarny AS and its competitors.
Is Pilulka Lekarny AS's Research & Development too high?
Pilulka Lekarny AS's current Research & Development is Kč0 Mil. Overall, Pilulka Lekarny AS has a GF Score™ of 49/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pilulka Lekarny AS's Research & Development compare to competitors?
Pilulka Lekarny AS's Research & Development of Kč0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Pilulka Lekarny AS and its competitors. Pilulka Lekarny AS's current Research & Development is Kč0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pilulka Lekarny AS stock overvalued right now?
Based on GuruFocus' analysis, Pilulka Lekarny AS (XPRA:PINK) is currently considered Fairly Valued. The stock's GF Value™ is Kč114.69, compared to a current price of Kč114.50 — trading 0.2% below its estimated fair value. The current Research & Development is Kč0 Mil. Pilulka Lekarny AS's overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Pilulka Lekarny AS (XPRA:PINK), the current Research & Development is Kč0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pilulka Lekarny AS (XPRA:PINK) Overvalued in 2026?

Based on GuruFocus' analysis, Pilulka Lekarny AS stock appears to be undervalued. The current stock price of Kč114.50 is trading 0.2% below its estimated GF Value™ of Kč114.69. GuruFocus considers Pilulka Lekarny AS to be Fairly Valued.

Key valuation signals for XPRA:PINK:

  • Research & Development: Kč0 Mil
  • GF Value™: Kč114.69 vs. price of Kč114.50 (0.2% below fair value)
  • GF Score™: 49/100 with 6 warning signs

No single metric tells the full story. See the XPRA:PINK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pilulka Lekarny AS Business Description

Address Drahobejlova 1073/36, Prague, CZE, 190 00
Pilulka Lekarny AS operates an online pharmaceutical store by distribution of medicinal products. The store offers over-the-counter-drugs, dietary supplements, baby foods, mother care products, cosmetics, other prescription drugs, sport nutritional products, diagnostic test kits, orthopaedic supplies, first aid kits, and other related products.
49GF Score

Get the complete analysis for XPRA:PINK

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

Kč114.50
Price
Kč114.69
GF Value